

Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_76389
Title of the Manuscript:	Evaluation of Antidiabetic Activity of Polyherbal Formulation “Vasant Kusumakar Ras” on Alloxan-induced and Dexamethasone-induced Diabetic Rats
Type of the Article	Original Research Article

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://peerreviewcentral.com/page/manuscript-withdrawal-policy>)

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Compulsory REVISION comments	In the present article the authors showed that commercial preparation of Vasant Kusumakar Ras (VKS) has antidiabetic and antilipidemic effects in two models of experimental diabetes, such as rats treated with alloxan and rats treated with dexamethasone, here VKS diminishes glycemia, in contrast with the effect reported by Tamoli et al. (2020) (your reference 6), in a model of experimental diabetes induced in rats with streptozotocin. In these three models, VKS treatment improves dyslipidemia. Also Timoli et al. (2020) showed that VKS has antioxidant effect. In the present article, in discussion the authors could contrast their results with that reported on the model of streptozotocin, and discuss if the different glycemic effect of VKS are due to different levels of glycemia on the three models of experimental diabetes, or if these are due to variations in the formulations or doses of VKS	
Minor REVISION comments	In figures 2 and 5, the name in the Y axis must be CHOLESTEROL	
Optional/General comments	Authors only repeat the results in discussion section, they can say something about of possible compounds in VKS that could participate to diminish glucose, cholesterol, triglycerides, and LDL, for this journal is convenient to add more knowledge about these aspects. Note: With the two models of experimental diabetes, VKS diminishes blood glucose, and dyslipidemia, you say that one doses is better than the other (400 or 600 mg/Kg), in some graphics both doses seems almost equal, you may show the statistical analysis between both doses, in order to sustain your conclusion.	

Review Form 1.6

PART 2:

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i> Yes the authors established the next statement: ...all the animal experiments were carried out according to the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA) guidelines, Ministry of Environment and Forests, Government of India”	

Reviewer Details:

Name:	Rebeca Garcia Macedo
Department, University & Country	Instituto Mexicano Del Seguro Social, Mexico